Human Omentin-1 Administration Ameliorates Hypertensive Complications without Affecting Hypertension in Spontaneously Hypertensive Rats
Open Access
- 14 February 2023
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (4) , 3835
Abstract
Hypertension is one of the major risk factors for cardiovascular diseases and is caused by various abnormalities including the contractility of blood vessels. Spontaneously hypertensive rats (SHR), whose systemic blood pressure increases with aging, are a frequently used animal model for investigating essential hypertension and related complications in humans due to the damage of several organs. Human omentin-1 is an adipocytokine consisting of 313 amino acids. Serum omentin-1 levels decreased in hypertensive patients compared with normotensive controls. Furthermore, omentin-1 knockout mice showed elevated blood pressure and impaired endothelial vasodilation. Taken together, we hypothesized that adipocytokine, human omentin-1 may improve the hypertension and its complications including heart and renal failure in the aged SHR (65–68-weeks-old). SHR were subcutaneously administered with human omentin-1 (18 μg/kg/day, 2 weeks). Human omentin-1 had no effect on body weight, heart rate, and systolic blood pressure in SHR. The measurement of isometric contraction revealed that human omentin-1 had no influence on the enhanced vasocontractile or impaired vasodilator responses in the isolated thoracic aorta from SHR. On the other hand, human omentin-1 tended to improve left ventricular diastolic failure and renal failure in SHR. In summary, human omentin-1 tended to improve hypertensive complications (heart and renal failure), while it had no influence on the severe hypertension in the aged SHR. The further study of human omentin-1 may lead to the development of therapeutic agents for hypertensive complications.Keywords
Funding Information
- Kitasato University Research Grant
This publication has 33 references indexed in Scilit:
- A novel adipocytokine, omentin, inhibits platelet-derived growth factor-BB-induced vascular smooth muscle cell migration through antioxidative mechanismAmerican Journal of Physiology-Heart and Circulatory Physiology, 2014
- Omentin Prevents Myocardial Ischemic Injury Through AMP-Activated Protein Kinase- and Akt-Dependent MechanismsJACC, 2014
- Omentin plays an anti-inflammatory role through inhibition of TNF-α-induced superoxide production in vascular smooth muscle cellsEuropean Journal of Pharmacology, 2012
- Diastolic dysfunction is associated with cardiac fibrosis in the senescence-accelerated mouseAmerican Journal of Physiology-Heart and Circulatory Physiology, 2011
- Omentin, a novel adipocytokine inhibits TNF-induced vascular inflammation in human endothelial cellsBiochemical and Biophysical Research Communications, 2011
- Transcriptional changes associated with recovery from heart failure in the SHRJournal of Molecular and Cellular Cardiology, 2010
- Omentin, a novel adipokine, induces vasodilation in rat isolated blood vesselsBiochemical and Biophysical Research Communications, 2010
- Genomic structure of human omentin, a new adipocytokine expressed in omental adipose tissueBiochimica et Biophysica Acta (BBA) - Gene Structure and Expression, 2005
- Rat models of hypertension, cardiac hypertrophy and failureCardiovascular Research, 1998
- The Renal Effects of Sodium Nitroprusside in Postoperative Cardiac Surgical PatientsAnesthesiology, 1981